Similarly, asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NOS, is elevated in metabolic syndrome and cardiovascular diseases, signaling reduced NO bioavailability [82,83]. This evidence concerns the gene NOS1 and cardiovascular disorder.